Ocular inflammatory events following COVID-19 vaccination: a multinational case series

• Autor(a) principal: Ilaria Testi
• Data de Publicação: 2022
• Outros Autores: Carl Herbort, Luca Cimino, Salam Iriqat, Jennifer e. Thorne, Jose Echegaray, Kalpana Babu, Alexander Arthur Bialasiewicz, Debra a. Goldstein, Nima Ghadiri, Alex Fonollosa Calduch, Camilo Brandão-de-resende, Gabriel Costa de Andrade, Padmamalini Mahendradas, Julio j. González-lópez, Ester Carreño, Rola n. Hamam, Nicole Stübiger, Bahram Bodaghi, Yu-jang Chao, Masaru Takeuchi, Mei-ling Tay-kearney, Rupesh Agrawal, Alejandro Portero, Hiroshi Keino, Mar Esteban-ortega, Joanna Prze'dziecka-do'yk, Aleksandra Radosavljevi', Ian Paredes, ho su Ling, Wei Kiong, Melissa Tien, Carlos Pavesio, Xin le ng, Soon Phaik Chee, Jay Siak, Ines Hernanz-rodriguez, Victor Menezo, Christoph Tappeiner, Franz Marie Cruz, Peter Addison, Laura Steeples, Robert Kuijpers, Daniel Vítor de Vasconcelos Santos, Balini Balasubramaniam, Peter Mccluskey, Francesco Pichi, Aniruddha Agarwal
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1186/s12348-021-00275-x; http://hdl.handle.net/1843/61800; https://orcid.org/0000-0002-6747-2024
• topic: Uveitis; Ocular inflammation; Immunomodulatory; Coronavirus disease; COVID-19; SARS-CoV-2; Vaccination; COVID-19; Vacinação; SARS-CoV-2; Inflamação; Uveíte

Background Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.